bluebird bio is actively pursuing outcomes-based contracts for its Zynteglo gene therapy for beta thalassemia in the US, if cleared for marketing, which could serve as an important precedent for the feasibility of outcomes-based contracts for such cutting edge therapies, according to UnitedHealthcare Pharmacy director of emerging therapeutics and outcomes-based contracting Erik Schindler.
Prospects for outcomes-based, risk-sharing contracts for cell and gene therapies in general “are promising, are moving forward, and this is...